Literature DB >> 18392317

Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival.

A Linecker1, C Kermer, I Sulzbacher, P Angelberger, K Kletter, R Dudczak, R Ewers, A Becherer.   

Abstract

UNLABELLED: The aim of the study was to determine the practicability of (18)F-FLT in tumours of the head and neck area in terms of visualization, a possible correlation between FLT uptake and proliferation fraction as determined by Ki-67 immunostaining, and if tumoural FLT-uptake has a prognostic meaning, as determined by a correlation to patient survival time. Results were compared to (18)F-FDG. PATIENTS,
METHODS: 20 patients with previously untreated lesions of the head and neck area, which were clinically highly suspicious to be malignant, underwent PET scans with (18)F-FLT and (18)F-FDG, a CT of the head and neck area, and a biopsy. Tumour tracer uptake was determined by standardized uptake value (SUV) normalized to body weight and /non-tumor ratios (T/N). (18)F-FDG and (18)F-FLT uptake were compared with histopathologic and immunohistochemical results.
RESULTS: 19 patients had malignant tumours; one patient had a benign cystadenoma (so called Warthin's tumour) of the parotid gland. One negative lesion turned out to be a malignant T1 stage squamous cell carcinoma in both PET scans, the Warthin's tumour was false positive with (18)F-FDG but showed only faint uptake with (18)F-FLT, resulting in a sensitivity of 95 % for both tracers. Of all lesions, maximum SUVs of (18)F-FLT ranged from 1.53 to 11.70 (mean +/- SD 5.81 +/- 2.28) those of FDG from 2.63 to 16.50 (mean +/- SD 8.91 +/- 3.58), p < 0.001. (18)F-FLT-T/N ranged from 0.94 to 5.85 (mean +/- SD, 3.18 +/- 1.21), (18)F-FDG-T/N was from 0.92 to 7.50 (mean +/- SD, 3.6 +/- 1.74), n.s. The mean survival time was 18 months in a maximum follow up time of 36 months. A significant correlation between both PET tracers and survival was detected, but no correlation between the amount of Ki-67 positive cells and FLT.
CONCLUSION: In head and neck cancer in the primary setting (18)F-FLT does not provide additional visual information in comparison to (18)F-FDG.(18)F-FLT uptake is inversely correlated with patient survival, as well as (18)F-FDG.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18392317     DOI: 10.3413/nukmed-0092

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  17 in total

Review 1.  Biologic imaging of head and neck cancer: the present and the future.

Authors:  A Srinivasan; S Mohan; S K Mukherji
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-22       Impact factor: 3.825

Review 2.  Non-invasive imaging of angiogenesis in head and neck squamous cell carcinoma.

Authors:  Jacobus F A Jansen; Jason A Koutcher; Amita Shukla-Dave
Journal:  Angiogenesis       Date:  2010-04-11       Impact factor: 9.596

3.  18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis.

Authors:  Peng Xie; Minghuan Li; Hanxi Zhao; Xindong Sun; Zheng Fu; Jinming Yu
Journal:  J Cancer Res Clin Oncol       Date:  2011-01-13       Impact factor: 4.553

4.  Comparison of FLT-PET and FDG-PET for visualization of head and neck squamous cell cancers.

Authors:  Hiroshi Hoshikawa; Yoshihiro Nishiyama; Takehito Kishino; Yuka Yamamoto; Reiji Haba; Nozomu Mori
Journal:  Mol Imaging Biol       Date:  2011-02       Impact factor: 3.488

5.  Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx.

Authors:  Matthew J Nyflot; Paul M Harari; Stephen Yip; Scott B Perlman; Robert Jeraj
Journal:  Radiother Oncol       Date:  2012-10-13       Impact factor: 6.280

6.  ⁹⁹mTc-N4amG: synthesis biodistribution and imaging in breast tumor-bearing rodents.

Authors:  Ning Tsao; Mithu Chanda; Dong-Fang Yu; Hiroaki Kurihara; Yin-Han Zhang; Richard Mendez; David J Yang
Journal:  Appl Radiat Isot       Date:  2012-10-11       Impact factor: 1.513

7.  Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.

Authors:  Neale S Mason; Brian J Lopresti; James Ruszkiewicz; Xinxin Dong; Sonali Joyce; George Leef; Malabika Sen; Abdus S Wahed; Chester A Mathis; Jennifer R Grandis; Sufi M Thomas
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-01-05

Review 8.  Alternative PET tracers in head and neck cancer. A review.

Authors:  Jan Wedman; Jan Pruim; Jan L N Roodenburg; Gyorgy B Halmos; Johannes A Langedijk; Rudi A J O Dierckx; Bernard F A M van der Laan
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-12-27       Impact factor: 2.503

9.  Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy.

Authors:  Yusuf Menda; Laura L Boles Ponto; Kenneth J Dornfeld; Timothy J Tewson; G Leonard Watkins; Michael K Schultz; John J Sunderland; Michael M Graham; John M Buatti
Journal:  J Nucl Med       Date:  2009-06-12       Impact factor: 10.057

10.  Recent advances in image-guided radiotherapy for head and neck carcinoma.

Authors:  Sameer K Nath; Daniel R Simpson; Brent S Rose; Ajay P Sandhu
Journal:  J Oncol       Date:  2009-07-29       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.